|
License Agreements (Details)
|
12 Months Ended | 1 Months Ended | 12 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2014
USD ($)
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Jun. 30, 2006
Eisai
License Agreement
USD ($)
|
Dec. 31, 2014
Eisai
License Agreement
|
Dec. 31, 2014
Eisai
License Agreement
Minimum
USD ($)
|
Dec. 31, 2014
Eisai
License Agreement
Maximum
USD ($)
|
Dec. 31, 2014
Clinical Trial Services Agreement
Ipsen
USD ($)
|
Dec. 31, 2013
Clinical Trial Services Agreement
Ipsen
USD ($)
|
Dec. 31, 2012
Clinical Trial Services Agreement
Ipsen
USD ($)
|
Dec. 31, 2005
Clinical Trial Services Agreement
Ipsen
USD ($)
|
Dec. 31, 2014
Clinical Trial Services Agreement
Ipsen
Minimum
USD ($)
|
Dec. 31, 2014
Clinical Trial Services Agreement
Ipsen
Minimum
EUR (€)
|
Dec. 31, 2014
Clinical Trial Services Agreement
Ipsen
Maximum
USD ($)
|
Dec. 31, 2014
Clinical Trial Services Agreement
Ipsen
Maximum
EUR (€)
|
Dec. 31, 2014
Clinical Trial Services Agreement
Ipsen
Sublicense Agreement
Maximum
|
|
| License Agreements | ||||||||||||||||
| Nonrefundable, non-creditable payment | $ 250,000 | |||||||||||||||
| Additional payments to be made upon achievement of certain development and commercialization milestones | 12,100,000 | 10,000,000 | 43,600,000 | 36,000,000 | ||||||||||||
| Royalty rate (as a percent) | 5.00% | |||||||||||||||
| Period after the date of the first commercial sale of the product for license expiration | 10 years | 10 years | 10 years | 10 years | ||||||||||||
| Amount recorded in research and development expense | 45,719,000 | 60,536,000 | 54,961,000 | 500,000 | 200,000 | 700,000 | ||||||||||
| Initial license fee paid | 500,000 | |||||||||||||||
| Payments to be made upon achievement of certain clinical and regulatory milestones | $ 1,000,000 | $ 20,000,000 | ||||||||||||||